Medicare Enrolled

Dr. Mohsen Ghadimi-Mahani, M.D.

Medical Oncology · Laredo, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
1710 E. SAUNDERS ST. SUITE A 140, Laredo, TX 78041
9567963580
In practice since 2008 (17 years)
NPI: 1881845253 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ghadimi-Mahani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ghadimi-Mahani? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ghadimi-Mahani

Dr. Mohsen Ghadimi-Mahani is a medical oncology in Laredo, TX, with 17 years in practice. Based on federal Medicare data, Dr. Ghadimi-Mahani performed 2,710 Medicare services across 861 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ghadimi-Mahani received a total of $16,775 from 68 pharmaceutical and/or device companies across 757 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ghadimi-Mahani is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 17 years in practice▲ Top 46% volume in TX$ $16,775 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,710
Medicare services
Top 46% in TX for medical oncology
861
Unique beneficiaries
$75
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~159 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (30-39 min)1,155$85$283
Hospital follow-up visit, moderate complexity968$60$194
Office visit, established patient (20-29 min)248$57$192
Initial hospital admission, moderate complexity225$95$370
Initial hospital admission, high complexity52$122$545
New patient office visit (45-59 min)29$120$438
New patient office visit (30-44 min)19$82$283
Hospital follow-up visit, high complexity14$93$279
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$16,775
Total received (2018-2024)
Avg $2,396/year across 7 years
Top 32% in TX for medical oncology
68
Companies
757
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,078 (89.9%)
Other
Charitable contributions, space rental, and other categories
$1,047 (6.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$649 (3.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,336
2023
$932
2022
$3,550
2021
$1,484
2020
$1,026
2019
$3,122
2018
$4,325

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$4,032
PFIZER INC.
$1,505
Janssen Biotech, Inc.
$1,184
Amgen Inc.
$898
AstraZeneca Pharmaceuticals LP
$858
Astellas Pharma US Inc
$662
E.R. Squibb & Sons, L.L.C.
$594
Lilly USA, LLC
$547
Celgene Corporation
$502
NOVARTIS PHARMACEUTICALS CORPORATION
$446
Merck Sharp & Dohme LLC
$362
GENZYME CORPORATION
$355
Seagen Inc.
$289
Takeda Pharmaceuticals U.S.A., Inc.
$268
Genentech USA, Inc.
$242
Merck Sharp & Dohme Corporation
$234
EISAI INC.
$196
Boehringer Ingelheim Pharmaceuticals, Inc.
$180
Verastem, Inc.
$165
Bayer HealthCare Pharmaceuticals Inc.
$154
Karyopharm Therapeutics Inc.
$151
Puma Biotechnology, Inc.
$148
Bayer Healthcare Pharmaceuticals Inc.
$146
Teva Pharmaceuticals USA, Inc.
$146
Kite Pharma, Inc.
$144
Incyte Corporation
$139
Gilead Sciences, Inc.
$135
AVEO Pharmaceuticals, Inc.
$133
Daiichi Sankyo Inc.
$108
Janssen Scientific Affairs, LLC
$107
Janssen Pharmaceuticals, Inc
$105
GlaxoSmithKline, LLC.
$103
SANOFI-AVENTIS U.S. LLC
$100
Eisai Inc.
$98
Exelixis Inc.
$96
AbbVie, Inc.
$86
PharmaEssentia USA Corporation
$84
PUMA BIOTECHNOLOGY, INC.
$82
ADC Therapeutics America, Inc.
$82
Array BioPharma Inc.
$76
Seattle Genetics, Inc.
$65
EMD Serono, Inc.
$53
Sumitomo Pharma America, Inc.
$52
AMAG Pharmaceuticals, Inc.
$49
Pharmacyclics LLC, An AbbVie Company
$48
ABBVIE INC.
$44
ARRAY BIOPHARMA INC
$44
Stemline Therapeutics Inc.
$42
JAZZ PHARMACEUTICALS INC.
$36
Rigel Pharmaceuticals, Inc.
$34
Octapharma USA, Inc.
$34
Dova Pharmaceuticals
$32
TESARO, Inc.
$29
Regeneron Healthcare Solutions, Inc.
$22
SOBI, INC
$22
AbbVie Inc.
$20
Aveo Pharmaceuticals, Inc.
$20
BeiGene USA, Inc.
$19
TOLMAR Pharmaceuticals, Inc.
$19
Clovis Oncology, Inc.
$19
Fennec Pharmaceuticals, Inc.
$18
APTEVO THERAPEUTICS INC
$18
TAIHO ONCOLOGY, INC.
$17
Immunocore Limited
$17
Ipsen Biopharmaceuticals, Inc
$17
TerSera Therapeutics LLC
$16
Nestle HealthCare Nutrition Inc.
$16
Foundation Medicine, Inc.
$14
Top 3 companies account for 40.1% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Aliqopa · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CALQUENCE · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · EMEND · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · Enhertu · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · IXINITY · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONUREG · OPDIVO · ORGOVYX · Orserdu · PADCEV · PANZYGA · PIQRAY · PROMACTA · Padcev · Pedmark · Perjeta · Pomalyst · Prolia · REBLOZYL · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · SUTENT · Stivarga · TAGRISSO · TALVEY · TASIGNA · TECENTRIQ · TIVDAK · TUKYSA · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZENPEP · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $619 per 100 Medicare services performed
Looking for a medical oncology in Laredo?
Compare medical oncologys in the Laredo area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
1
Per 100K population
0.4
County median income
$62,506
Nearest hospital
DOCTORS HOSPITAL OF LAREDO
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Ghadimi-Mahani is a clinical cardiology specialist, with moderate Medicare volume, and low-engagement industry engagement, with 17 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Ghadimi-Mahani experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Ghadimi-Mahani performed 1,155 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ghadimi-Mahani receive payments from pharmaceutical companies?
Yes. Dr. Ghadimi-Mahani received a total of $16,775 from 68 companies across 757 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ghadimi-Mahani's costs compare to other medical oncologys in Laredo?
Dr. Ghadimi-Mahani's average Medicare payment per service is $75. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ghadimi-Mahani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →